Challenges of targeting A beta fibrillogenesis and other protein folding disorders.

The Amyloid Hypothesis and the clearance and degradation of Alzheimer's beta-peptide.

Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites.

Similar promotion of Abeta1-42 fibrillogenesis by native apolipoprotein E epsilon3 and epsilon4 isoforms.

Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.

Emerging prospects for the disease-modifying treatment of Alzheimer's disease.

Multiple ligand binding sites on A beta(1-40) fibrils.

Inducible proteopathies.

Small molecule inhibitors of Abeta assembly.

Diversity of Abeta deposits in the aged brain: a window on molecular heterogeneity?